LA Private

September 2024

Stocks of the Hour: Imugene, RocketDNA, Marquee Resources

Imugene (ASX:IMU) announced promising results from its Phase 1b clinical trial with azer-cel, in patients with relapsed/refractory diffuse large B cell lymphoma. All enrolled patients had cancer that had returned following autologous CAR T therapy, a high unmet need for this patient population. Shares are trading 25.81 per cent higher at 7.8 cents. RocketDNA (ASX:RKT) […]

Stocks of the Hour: Imugene, RocketDNA, Marquee Resources Read More »